Sandoz Finalizes Purchase of Just-Evotec Biologics
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 08 2025
0mins
Should l Buy ?
Source: NASDAQ.COM
Acquisition Announcement: Sandoz has completed the acquisition of Just-Evotec Biologics EU SAS, which includes a development and manufacturing site in Toulouse and a license for advanced continuous-manufacturing technology for biosimilars.
Strategic Alignment: The acquisition aligns with Sandoz's biosimilar strategy, enhancing its in-house drug substance development and manufacturing capabilities while improving efficiency and scalability through the new technology.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
